{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:51:38Z","timestamp":1775494298041,"version":"3.50.1"},"reference-count":48,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0007","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:12:21Z","timestamp":1774339941000},"source":"Crossref","is-referenced-by-count":1,"title":["Central serous chorioretinopathy: Etiology, diagnosis, and treatment"],"prefix":"10.3238","author":[{"given":"Clemens","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Lahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurenz","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"10.3238\/arztebl.m2026.0007_ref1","doi-asserted-by":"crossref","unstructured":"Lange CA, Ohlmeier C, Kisk\u00e4mper A, et al.: Clinical landscape of central serous chorioretinopathy in Germany: Retina.net CSC registry report number 1. Ophthalmologica 2024; 247: 95&#8211;106.","DOI":"10.1159\/000535930"},{"key":"10.3238\/arztebl.m2026.0007_ref2","doi-asserted-by":"crossref","unstructured":"Frederiksen IN, Muttuvelu DV, Anguita R, et al.: Prevalence of central serous chorioretinopathy in Denmark. Acta Ophthalmol 2025; 103: 776&#8211;81.","DOI":"10.1111\/aos.17520"},{"key":"10.3238\/arztebl.m2026.0007_ref3","unstructured":"von Graefe A: Die zentrale rezidivierende Retinitis. Arch Clin Exp Ophthalmol 1866; 12: 221."},{"key":"10.3238\/arztebl.m2026.0007_ref4","doi-asserted-by":"crossref","unstructured":"Liu B, Deng T, Zhang J: Risk factors for central serous chorioretinopathy: A systematic review and meta-analysis. Retina 2016; 36: 9&#8211;19.","DOI":"10.1097\/IAE.0000000000000837"},{"key":"10.3238\/arztebl.m2026.0007_ref5","doi-asserted-by":"crossref","unstructured":"Pauleikhoff LJB, Diederen RMH, Chang-Wolf JM, et al.: Choroidal vascular changes on ultrawidefield indocyanine green angiography in central serous chorioretinopathy: CERTAIN Study Report 1. Ophthalmol Retina 2024; 8: 254&#8211;63.","DOI":"10.1016\/j.oret.2023.10.007"},{"key":"10.3238\/arztebl.m2026.0007_ref6","doi-asserted-by":"crossref","unstructured":"Spaide RF, Gemmy Cheung CM, Matsumoto H, et al.: Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 2022; 86: 100973.","DOI":"10.1016\/j.preteyeres.2021.100973"},{"key":"10.3238\/arztebl.m2026.0007_ref7","doi-asserted-by":"crossref","unstructured":"Cheung CMG, Dansingani KK, Koizumi H, et al.: Pachychoroid disease: Review and update. Eye (Lond) 2025; 39: 819&#8211;34.","DOI":"10.1038\/s41433-024-03253-4"},{"key":"10.3238\/arztebl.m2026.0007_ref8","doi-asserted-by":"crossref","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB: Pachychoroid disease. Eye (Lond) 2019; 33: 14&#8211;33.","DOI":"10.1038\/s41433-018-0158-4"},{"key":"10.3238\/arztebl.m2026.0007_ref9","doi-asserted-by":"crossref","unstructured":"Spaide RF, Ledesma-Gil G, Gemmy Cheung CM: Intervortex venous anastomosis in pachychoroid-related disorders. Retina 2021; 41: 997&#8211;1004.","DOI":"10.1097\/IAE.0000000000003004"},{"key":"10.3238\/arztebl.m2026.0007_ref10","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Vigo JI, Rego-Lorca D, Moreno-Morillo FJ, et al.: Intervortex venous anastomosis in the macula in central serous chorioretinopathy imaged by en face optical coherence tomography. J Clin Med 2023; 12: 2088.","DOI":"10.3390\/jcm12062088"},{"key":"10.3238\/arztebl.m2026.0007_ref11","doi-asserted-by":"crossref","unstructured":"R\u00e4m\u00f6 JT, Gorman BR, Weng LC, et al.: Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma. Nat Commun 2025; 16: 4127.","DOI":"10.1038\/s41467-025-58686-6"},{"key":"10.3238\/arztebl.m2026.0007_ref12","unstructured":"Pauleikhoff L, Hufnagel H, Lange C: [Imaging and classification of central serous chorioretinopathy&#8212;What do I really need?]. Ophthalmologie 2025; 122: 172&#8211;7."},{"key":"10.3238\/arztebl.m2026.0007_ref13","unstructured":"Lange C, Aschauer J, Hufnagel H, Pauleikhoff L, Retina.net CSC-Registry-Studie Gruppe: [Differential diagnoses of central serous chorioretinopathy: Is that really a central serous chorioretinopathy?]. Ophthalmologie 2025; 122: 178&#8211;85."},{"key":"10.3238\/arztebl.m2026.0007_ref14","doi-asserted-by":"crossref","unstructured":"Daruich A, Matet A, Marchionno L, et al.: Acute central serous chorioretinopathy: Factors influencing episode duration. Retina 2017; 37: 1905&#8211;15.","DOI":"10.1097\/IAE.0000000000001443"},{"key":"10.3238\/arztebl.m2026.0007_ref15","doi-asserted-by":"crossref","unstructured":"Matet A, Daruich A, Zola M, Behar-Cohen F: Risk factors for recurrences of central serous chorioretinopathy. Retina 2018; 38: 1403&#8211;14.","DOI":"10.1097\/IAE.0000000000001729"},{"key":"10.3238\/arztebl.m2026.0007_ref16","doi-asserted-by":"crossref","unstructured":"Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A: Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res 2020; 79: 100865.","DOI":"10.1016\/j.preteyeres.2020.100865"},{"key":"10.3238\/arztebl.m2026.0007_ref17","doi-asserted-by":"crossref","unstructured":"Giusti C: Association of helicobacter pylori with central serous chorioretinopathy: Hypotheses regarding pathogenesis. Med Hypotheses 2004; 63: 524&#8211;7.","DOI":"10.1016\/j.mehy.2004.02.020"},{"key":"10.3238\/arztebl.m2026.0007_ref18","doi-asserted-by":"crossref","unstructured":"Cunningham ET, Alfred PR, Irvine AR: Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology 1996; 103: 2081&#8211;90.","DOI":"10.1016\/S0161-6420(96)30385-0"},{"key":"10.3238\/arztebl.m2026.0007_ref19","doi-asserted-by":"crossref","unstructured":"Liu PK, Chang YC, Tai MH, et al.: The association between central serous chorioretinopathy and sleep apnea: A nationwide population-based study. Retina 2020; 40: 2034&#8211;44.","DOI":"10.1097\/IAE.0000000000002702"},{"key":"10.3238\/arztebl.m2026.0007_ref20","doi-asserted-by":"crossref","unstructured":"van Haalen FM, van Dijk EHC, Savas M, et al.: Hair cortisol concentrations in chronic central serous chorioretinopathy. Acta Ophthalmol 2020; 98: 390&#8211;5.","DOI":"10.1111\/aos.14269"},{"key":"10.3238\/arztebl.m2026.0007_ref21","doi-asserted-by":"crossref","unstructured":"Kirschbaum C, Pirke KM, Hellhammer DH: The &#8217;Trier Social Stress Test&#8217;&#8212;a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993; 28: 76&#8211;81.","DOI":"10.1159\/000119004"},{"key":"10.3238\/arztebl.m2026.0007_ref22","doi-asserted-by":"crossref","unstructured":"Yannuzzi LA: Type-A behavior and central serous chorioretinopathy. Retina 1987; 7: 111&#8211;31.","DOI":"10.1097\/00006982-198700720-00009"},{"key":"10.3238\/arztebl.m2026.0007_ref23","doi-asserted-by":"crossref","unstructured":"Friedman M, Rosenman RH: Association of specific overt behavior pattern with blood and cardiovascular findings; blood cholesterol level, blood clotting time, incidence of arcus senilis, and clinical coronary artery disease. J Am Med Assoc 1959; 169: 1286&#8211;96.","DOI":"10.1001\/jama.1959.03000290012005"},{"key":"10.3238\/arztebl.m2026.0007_ref24","doi-asserted-by":"crossref","unstructured":"Hufnagel HJ, Lahmann C, Agostini H, Lange C, Pauleikhoff LJB, Retina.net CCS study group: Psychometric assessment of patients with central serous chorioretinopathy and correlation with disease stage and progression: A case control study. BMC Ophthalmol 2024; 24: 92.","DOI":"10.1186\/s12886-024-03356-2"},{"key":"10.3238\/arztebl.m2026.0007_ref25","doi-asserted-by":"crossref","unstructured":"Sesar AP, Sesar A, Bucan K, Sesar I, Cvitkovic K, Cavar I: Personality traits, stress, and emotional intelligence associated with central serous chorioretinopathy. Med Sci Monit 2021; 27: e928677.","DOI":"10.12659\/MSM.928677"},{"key":"10.3238\/arztebl.m2026.0007_ref26","doi-asserted-by":"crossref","unstructured":"van Haalen FM, van Dijk EHC, Andela CD, et al.: Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. Acta Ophthalmol 2019; 97: e572&#8211;e9.","DOI":"10.1111\/aos.13952"},{"key":"10.3238\/arztebl.m2026.0007_ref27","doi-asserted-by":"crossref","unstructured":"Fok ACT, Chan PPM, Lam DSC, Lai TYY: Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 2011; 46: 160&#8211;3.","DOI":"10.1159\/000324599"},{"key":"10.3238\/arztebl.m2026.0007_ref28","doi-asserted-by":"crossref","unstructured":"Kim YK, Woo SJ, Park KH, Chi YK, Han JW, Kim KW: Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype. Korean J Ophthalmol 2018; 32: 281&#8211;9.","DOI":"10.3341\/kjo.2017.0144"},{"key":"10.3238\/arztebl.m2026.0007_ref29","unstructured":"Hufnagel HJ, Lahmann C, Pauleikhoff L, Lange C, Retina.net CCS-Register-Studiengruppe: [Stress and other risk factors in central serous chorioretinopathy-A myth?]. Ophthalmologie 2025; 122: 162&#8211;9."},{"key":"10.3238\/arztebl.m2026.0007_ref30","doi-asserted-by":"crossref","unstructured":"Sabel BA, Wang J, C\u00e1rdenas-Morales L, Faiq M, Heim C: Mental stress as consequence and cause of vision loss: The dawn of psychosomatic ophthalmology for preventive and personalized medicine. EPMA J 2018; 9: 133&#8211;60.","DOI":"10.1007\/s13167-018-0136-8"},{"key":"10.3238\/arztebl.m2026.0007_ref31","unstructured":"Schultz-Zehden W: Das Auge &#8211; Spiegel der Seele. Neue Wege zur Ganzheitstherapie. M\u00fcnchen: DTV 1995."},{"key":"10.3238\/arztebl.m2026.0007_ref32","doi-asserted-by":"crossref","unstructured":"Emmerich G: [Psychosomatics in ophthalmology &#8211; Diagnosis and Treatments]. Klin Monbl Augenheilkd 2012; 229: e33&#8211;e51.","DOI":"10.1055\/s-0032-1315138"},{"key":"10.3238\/arztebl.m2026.0007_ref33","doi-asserted-by":"crossref","unstructured":"Professional Association of German Ophthalmologists (Berufsverband der Augen\u00e4rzte Deutschlands e.V., BVA); German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG); German Retina Society e.V. (Retinologische Gesellschaft e.V., RG). Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy: Status 18 October 2021. Ophthalmologie 2022; 119 (Suppl 2): 108&#8211;22.","DOI":"10.1007\/s00347-022-01614-6"},{"key":"10.3238\/arztebl.m2026.0007_ref34","doi-asserted-by":"crossref","unstructured":"Feenstra HMA, van Dijk EHC, Cheung CMG, et al.: Central serous chorioretinopathy: An evidence-based treatment guideline. Prog Retin Eye Res 2024; 101: 101236.","DOI":"10.1016\/j.preteyeres.2024.101236"},{"key":"10.3238\/arztebl.m2026.0007_ref35","doi-asserted-by":"crossref","unstructured":"van Dijk EHC, Fauser S, Breukink MB, et al.: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy. Ophthalmology 2018; 125: 1547&#8211;55.","DOI":"10.1016\/j.ophtha.2018.04.021"},{"key":"10.3238\/arztebl.m2026.0007_ref36","doi-asserted-by":"crossref","unstructured":"van Rijssen TJ, van Dijk EHC, Tsonaka R, et al.: Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): A randomized controlled trial. Am J Ophthalmol 2022; 233: 101&#8211;10.","DOI":"10.1016\/j.ajo.2021.06.020"},{"key":"10.3238\/arztebl.m2026.0007_ref37","doi-asserted-by":"crossref","unstructured":"Pauleikhoff LJB, Chang-Wolf JM, Diederen RMH, et al.: Ultra-widefield indocyanine green angiographic changes after photodynamic therapy in central serous chorioretinopathy. CERTAIN study report 3. Retina 2025; 45: 1143&#8211;50.","DOI":"10.1097\/IAE.0000000000004414"},{"key":"10.3238\/arztebl.m2026.0007_ref38","doi-asserted-by":"crossref","unstructured":"Leaver P, Williams C: Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674&#8211;7.","DOI":"10.1136\/bjo.63.10.674"},{"key":"10.3238\/arztebl.m2026.0007_ref39","doi-asserted-by":"crossref","unstructured":"Lange CA, Qureshi R, Pauleikhoff L: Interventions for central serous chorioretinopathy: A network meta-analysis. Cochrane Database Syst Rev 2025; 6: CD011841.","DOI":"10.1002\/14651858.CD011841.pub3"},{"key":"10.3238\/arztebl.m2026.0007_ref40","doi-asserted-by":"crossref","unstructured":"Brelen ME, Ho M, Li S, et al.: Comparing half-dose photodynamic therapy with subthreshold micropulse laser for the treatment of central serous chorioretinopathy. Ophthalmol Retina 2024; 8: 490&#8211;8","DOI":"10.1016\/j.oret.2023.10.024"},{"key":"10.3238\/arztebl.m2026.0007_ref41","doi-asserted-by":"crossref","unstructured":"Kretz FTA, Beger I, Koch F, Nowomiejska K, Auffarth GU, Koss MJ: Randomized clinical trial to compare micropulse photocoagulation versus half-dose verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 837&#8211;43.","DOI":"10.3928\/23258160-20150909-08"},{"key":"10.3238\/arztebl.m2026.0007_ref42","doi-asserted-by":"crossref","unstructured":"Sun Z, Huang Y, Nie C, et al.: Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond) 2020; 34: 1592&#8211;9.","DOI":"10.1038\/s41433-019-0692-8"},{"key":"10.3238\/arztebl.m2026.0007_ref43","doi-asserted-by":"crossref","unstructured":"van Dijk EHC, Feenstra HMA, Bjerager J, Grauslund J, Boon CJF, Subhi Y: Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses. Acta Ophthalmol 2023; 101: 140&#8211;59.","DOI":"10.1111\/aos.15263"},{"key":"10.3238\/arztebl.m2026.0007_ref44","doi-asserted-by":"crossref","unstructured":"You EL, H\u00e9bert M, Jin TS, et al.: Comparing interventions for chronic central serous chorioretinopathy: A network meta-analysis. Surv Ophthalmol 2023; 68: 601&#8211;14.","DOI":"10.1016\/j.survophthal.2023.03.001"},{"key":"10.3238\/arztebl.m2026.0007_ref45","doi-asserted-by":"crossref","unstructured":"K\u00fcnzel SE, Kabiri P, Zur Bonsen L, et al.: Exploring non-modifiable and modifiable determinants of vision-related quality of life in central serous chorioretinopathy. J Clin Med 2024; 13: 4359.","DOI":"10.3390\/jcm13154359"},{"key":"10.3238\/arztebl.m2026.0007_ref46","unstructured":"Lotery A, Sivaprasad S, O&#8217;Connell A, et al.: Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 294&#8211;303."},{"key":"10.3238\/arztebl.m2026.0007_ref47","unstructured":"Brocks U, Ziegler M, Lange C, Altay L, Pauleikhoff L: [Secondary choroidal neovascularization-really so common?]. Ophthalmologie 2025; 122: 196&#8211;200."},{"key":"10.3238\/arztebl.m2026.0007_ref48","doi-asserted-by":"crossref","unstructured":"Lai TYY, Staurenghi G, Lanzetta P, et al.: Efficacy and safety of Ranibizumab for the treatment of choroidal neovasularisation due to uncommon cause: Twelve-Month Results of the MINERVA Study. Retina 2017; 38: 1464&#8211;77.","DOI":"10.1097\/IAE.0000000000001744"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:13:01Z","timestamp":1774339981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":48,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0007","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}